The treatment of Alzheimer's disease: The approach from a clinical specialist in the Trenches

Seminars in Neurology

Volumn 22, Issue 1, 2002, Pages 71-74

  Hake, Ann Marie ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Dementia; Therapy

Indexed keywords

ALPHA TOCOPHEROL; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DONEPEZIL; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; GALANTAMINE; LAMOTRIGINE; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SERTRALINE; TACRINE; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE;

AGING; ALZHEIMER DISEASE; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0036074623     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-33050     Document Type: Review

References (27)

1. Epidemiology of Alzheimer's disease
2. Epidemiology of dementia in Rochester, Minnesota
3. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
4. Selective loss of central cholinergic neurons in Alzheimer's disease
5. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
6. The effects of donepezil in Alzheimer's disease: Results from a multinational trial
7. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
8. A 5-month, randomized, placebo-controlled trial of galantamine in AD
9. Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension
10. New concepts in the drug therapy of Alzheimer's disease
11. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
12. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease
13. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study
14. Benefits of donepezil on global function, behavior, cognition, and ADLs in patients with moderate-to-severe Alzheimer's disease
15. Rivastigmine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: Findings from a 26-week trial
16. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
17. Aging and depression
18. Frequency and presentation of depressive symptoms in patients with primary degenerative dementia
19. Treatment of non-cognitive symptoms in dementia
20. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
21. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial: The HGEU Study Group
22. Neuroleptic sensitivity in patients with senile dementia of Lewy body type
23. Successful use of donepezil for the treatment of dementia with Lewy bodies
24. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
25. Assessment and management of behavioral disturbances in nursing home patients with dementia
26. A controlled trial of selegiline, alpha-tocopherol or both as treatment for Alzheimer's disease
27. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL